Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2024
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally grouped into three subtypes, constipation predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for IBS; few drugs have secured FDA approval for IBS-D, and most drugs used are off-label. Current treatment options comprise antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), an antibiotic (Salix Pharmaceuticals’ Xifaxan), and an opioid delta receptor antagonist (AbbVie’s Viberzi).
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
- How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: AbbVie, Salix, Sebela Pharmaceuticals
Key drugs: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
